Evidence map›Paper›PMID 42720258›Full record

Trial reportGut microbes2026

Probiotic supplementation increases fecal TLR4 agonists without improving disease activity in juvenile idiopathic arthritis: a randomized placebo-controlled trial.

Capucine Durand, Laurye-Anne Eveillard, Mathilde Labouret, Florence Aeschlimann, Alexandre Belot, Karine Brochard, Benoit Chassaing, Priscilla Boizeau, Rym Boulkedid, Aurélia Carbasse and 19 more

Abstract readRandomized Controlled TrialMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Gut microbes, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

29 authors.

Capucine DurandGeneral Paediatrics, Paediatric Internal Medicine, Rheumatology and Infectious Diseases Department, National Reference Centre for Rare Paediatric Inflammatory Rheumatisms and Systemic Autoimmune diseases (RAISE), Robert-Debré University Hospital, Assistance Publique-Hôpitaux de Paris (APHP), Paris, France.
Laurye-Anne EveillardGeneral Paediatrics, Paediatric Internal Medicine, Rheumatology and Infectious Diseases Department, National Reference Centre for Rare Paediatric Inflammatory Rheumatisms and Systemic Autoimmune diseases (RAISE), Robert-Debré University Hospital, Assistance Publique-Hôpitaux de Paris (APHP), Paris, France.
Mathilde LabouretGeneral Paediatrics, Paediatric Internal Medicine, Rheumatology and Infectious Diseases Department, National Reference Centre for Rare Paediatric Inflammatory Rheumatisms and Systemic Autoimmune diseases (RAISE), Robert-Debré University Hospital, Assistance Publique-Hôpitaux de Paris (APHP), Paris, France.
Florence AeschlimannDepartment of Rheumatology, University Children's Hospital Basel, Basel, Switzerland.
Alexandre BelotPaediatric Nephrology, Rheumatology, Dermatology Department, National Reference Centre for Rare Paediatric Inflammatory Rheumatisms and Systemic Autoimmune diseases (RAISE), Hôpital Femme Mère Enfant, Hospices Civils de Lyon, Bron Cedex, France.
Karine BrochardPaediatric Nephrology and Internal Medicine Unit, Children's Hospital, Toulouse, France.
Benoit ChassaingMicrobiome-Host Interactions, Institut Pasteur, Université Paris Cité, Paris, France.ORCID 0000-0002-4285-769X
Priscilla BoizeauAssistance Publique-Hôpitaux de Paris (AP-HP), Robert Debré Hospital, Clinical Epidemiology Unit, INSERM Clinical Investigation Center (CIC 1426), Paris, France.
Rym BoulkedidAssistance Publique-Hôpitaux de Paris (AP-HP), Robert Debré Hospital, Clinical Epidemiology Unit, INSERM Clinical Investigation Center (CIC 1426), Paris, France.
Aurélia CarbasseDepartment of Paediatrics, Arnaud-de-Villeneuve Hospital, Montpellier Regional and University Hospital, Montpellier, France.
Bilade CherqaouiPaediatrics Department, AP-HP, Ambroise Paré Hospital, Boulogne-Billancourt, France UMR1173, Université Versailles/Paris-Saclay, INSERM, Infection & Inflammation, Laboratory of Excellence INFIBREX, Montigny-Le-Bretonneux, France.
Cécile DumaineGeneral Paediatrics, Paediatric Internal Medicine, Rheumatology and Infectious Diseases Department, National Reference Centre for Rare Paediatric Inflammatory Rheumatisms and Systemic Autoimmune diseases (RAISE), Robert-Debré University Hospital, Assistance Publique-Hôpitaux de Paris (APHP), Paris, France.
Anne DumayUniversité Paris Cité, INSERM, Centre de Recherche sur l'inflammation, Paris, France.
Cécile FrachettePaediatric Nephrology, Rheumatology, Dermatology Department, National Reference Centre for Rare Paediatric Inflammatory Rheumatisms and Systemic Autoimmune diseases (RAISE), Hôpital Femme Mère Enfant, Hospices Civils de Lyon, Bron Cedex, France.
Véronique HentgenFrench Reference Centre for Autoinflammatory Diseases and Amyloidosis CEREMAIA and Competence center for Rare Paediatric Inflammatory Rheumatisms and Systemic Autoimmune diseases RAISE, Department of Paediatrics, Versailles Hospital, Le Chesnay, France.
Cécile KedziaClinical Research and Innovation Department, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France.
Therese KoltaAssistance Publique-Hôpitaux de Paris (AP-HP), Robert Debré Hospital, Clinical Epidemiology Unit, INSERM Clinical Investigation Center (CIC 1426), Paris, France.
Isabelle Koné-PautBicêtre University Hospital (APHP), Paediatric Rheumatology Department and CEREMAIA (Reference Centre for Auto-Inflammatory Diseases and Amyloidosis), Le Kremlin-Bicêtre, Paris, France.
Quentin Lamy-BesnierMicrobiome-Host Interactions, Institut Pasteur, Université Paris Cité, Paris, France.ORCID 0000-0002-7141-6340
Sophie Guilmin-CreponAssistance Publique-Hôpitaux de Paris (AP-HP), Robert Debré Hospital, Clinical Epidemiology Unit, INSERM Clinical Investigation Center (CIC 1426), Paris, France.
Lara Lima-AntoineUniversité Paris Cité, INSERM, Centre de Recherche sur l'inflammation, Paris, France.
Pascal PilletPaediatric Rheumatology Department, National Reference Centre for Rare Paediatric Inflammatory Rheumatisms and Systemic Autoimmune diseases (RAISE), Bordeaux University Hospital, Bordeaux, France.
Pierre QuartierPaediatric Immuno-Haematology and Rheumatology Unit, RAISE Reference Center (ERN RECONNECT), Hopital universitaire Necker-Enfants malades, Paris, France.
Stéphanie TellierPaediatric Nephrology and Internal Medicine Unit, Children's Hospital, Toulouse, France.
Julien Tourneur-MarsilleUniversité Paris Cité, INSERM, Centre de Recherche sur l'inflammation, Paris, France.
Heloise ReumauxPaediatric Rheumatology Unit, University of Lille, Jeanne de Flandre Hospital, Lille, France.
Caroline VinitGeneral Paediatrics, Paediatric Internal Medicine, Rheumatology and Infectious Diseases Department, National Reference Centre for Rare Paediatric Inflammatory Rheumatisms and Systemic Autoimmune diseases (RAISE), Robert-Debré University Hospital, Assistance Publique-Hôpitaux de Paris (APHP), Paris, France.
Emilie ViennoisUniversité Paris Cité, INSERM, Centre de Recherche sur l'inflammation, Paris, France.
Ulrich MeinzerGeneral Paediatrics, Paediatric Internal Medicine, Rheumatology and Infectious Diseases Department, National Reference Centre for Rare Paediatric Inflammatory Rheumatisms and Systemic Autoimmune diseases (RAISE), Robert-Debré University Hospital, Assistance Publique-Hôpitaux de Paris (APHP), Paris, France.ORCID 0000-0001-8539-6507

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Gut dysbiosis has been implicated in the pathogenesis of juvenile idiopathic arthritis (JIA), suggesting that microbiota-targeted interventions may influence immune signalling during early immune development. We conducted the PERMAJI multicentre randomized, double-blind, placebo-controlled trial to evaluate the effects of probiotic supplementation (VSL#3) on host-microbiota immune interactions and disease activity in children with oligoarticular or RF-negative polyarticular JIA. Participants were randomly assigned (1:1) to receive VSL#3 or placebo for 3 months in addition to standard therapy. Stool and serum samples collected at baseline and month 3 were used to assess gut microbiota composition, fecal innate immune agonists, intestinal permeability, and systemic cytokines. The primary clinical endpoint was the proportion achieving an ACR Pedi 30 response at 3 months. Forty-four children were enrolled between September 2017 and July 2022. Clinical responses did not differ between groups (ACR Pedi 30: 47% with VSL#3 vs 63% with placebo;

Indexed as

Arthritis, JuvenileFecesGastrointestinal MicrobiomeProbioticsToll-Like Receptor 4ChildChild, PreschoolCytokinesDietary SupplementsDouble-Blind MethodDysbiosisFemaleHumansMaleToll-Like Receptor AgonistsCytokinesTLR4 protein, humanToll-Like Receptor 4Toll-Like Receptor Agonistsgut microbiotainnate immunityjuvenile idiopathic arthritisProbioticsToll-like receptor 4 (TLR4)

Identifiers

PMID42720258
PMCPMC13568562

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.